Skip to content
Peptigraph home

CJC-1295 vs Ipamorelin: What the Research Shows

CJC-1295 and Ipamorelin side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.[5]Growth hormoneGHRP (ghrelin receptor agonist)Not FDA approved · research chemicalIpamorelinGhrelin-receptor agonist peptide, not FDA-approved; in a randomized trial after bowel resection, median time to first tolerated meal was 25.3 versus 32.6 hours with placebo.[13]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider CJC-1295 if…

  • you want randomized human hormone data (hormone levels, not a clinical benefit): a single injection raised mean plasma GH 2- to 10-fold for 6 days or more[5]

Consider Ipamorelin if…

  • you want the option with a randomized human trial, though it found no significant difference from placebo (postoperative ileus): median time to first tolerated meal was 25.3 h vs 32.6 h[13]

What they have in common

  • WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin[2]
  • WADA prohibits growth hormone secretagogues at all times; its list names ibutamoren (MK-677) and ipamorelin[2]
Neither is FDA approved for any use in people. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 7 of 13 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, WADA, Evidence strength, Vial sizes sold are the same or both unknown.

FieldCJC-1295Ipamorelin
ClassGHRH analogGHRP (ghrelin receptor agonist)
Also calledCJC, mod GRF, GRF 1-29ipa, ipam
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
  • A direct-urine screen includes ipamorelin among the peptides it can detect, at 50 to 500 pg/mL.PMID 26578461
Half-lifeNo published half-life foundPubMed search, 11 Oct 20262 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658
Human studies we summarised4 human (1 randomized or controlled) of 7 summarised2 human (2 randomized or controlled) of 12 summarised
Typical study doses
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

Sold mixed: CJC-1295 + Ipamorelin

These blends put both in one vial. The blend calculator works out the dose of each component per draw. Evidence for the combination: No studies tested these together (PubMed search: 10 results, 2 Oct 2026).

Blend calculator

Different receptors, different kinetics

Ipamorelin was described as the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.[17]

In that preclinical study, ipamorelin did not release ACTH or cortisol at levels significantly different from those after GHRH stimulation.[17]

In humans, ipamorelin's terminal half-life was reported as 2 hours.[12]

In a randomized healthy-adult study, CJC-1295's estimated half-life was 5.8-8.1 d.[5]

In the ipamorelin pharmacokinetic study, GH showed a single episode of release with a peak at 0.67 hours and an exponential decline to negligible concentration at all doses.[12]

After CJC-1295 administration, GH secretion was increased with preserved pulsatility.[6]

The human trials that exist for each

Ipamorelin's only randomized efficacy trial was a phase 2 study in bowel-resection patients, and the key and secondary efficacy analyses did not differ significantly from placebo.[13]

In the CJC-1295 trial, no serious adverse reactions were reported.[5]

After intranasal application in an animal study, ipamorelin's bioavailability was estimated at approximately 20%.[18]

Common questions

CJC-1295 vs ipamorelin: which is better?

Ipamorelin's phase 2 bowel-surgery trial found no significant differences from placebo in the key and secondary efficacy analyses; the cited CJC-1295 work consists of hormone studies.[13]

Why are CJC-1295 and ipamorelin sold together?

No trial of the pair is cited here. A review of unregulated use notes uncertainty about product composition, dose and stacking practices.[19]

How long does each stay active?

In the human study, ipamorelin's terminal half-life was 2 hours.[12]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  4. 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  5. 5Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  6. 6Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  7. 7Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  8. 8PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  11. 11Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
  12. 12Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  13. 13Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  14. 14The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
  15. 15PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  17. 17Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
  18. 18Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption.Xenobiotica; the fate of foreign compounds in biological systems · 1998PMID 9879640Accessed 2 Oct 2026
  19. 19The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026

Found an error? Report a correction.